NCT05490017View on ClinicalTrials.gov

To Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Escalating Single and Multiple Doses of KP104

PHASE1CompletedINTERVENTIONAL
Enrollment

80

Participants

Timeline

Start Date

December 30, 2020

Primary Completion Date

May 4, 2022

Study Completion Date

September 2, 2022

Conditions
Paroxysmal Nocturnal Hemoglobinuria
Interventions
DRUG

KP104

Participants will receive KP104 intravenous (IV) dose approximately for 1 hour or subcutaneous (SC) dose.

DRUG

Placebo

Participants will receive matching placebo which is KP104 vehicle containing sodium phosphate, sodium chloride, and L-Lysine Hydrochloride (L-Lys-HCL).

Trial Locations (1)

Unknown

CMAX Clinical Research, Adelaide

Sponsors
All Listed Sponsors
lead

Kira Pharmacenticals (US), LLC.

INDUSTRY